UBS Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

UBS Group’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,000	Closed	-$239K	–	8732
2019 Q4	$239K	Hold	10,000	–	–	﹤0.01%	5476
2019 Q3	$268K	Buy	+10,000	New	+$281K	﹤0.01%	5028
2017 Q1	–	Sell	-252,000	Closed	-$5.66M	–	8163
2016 Q4	$5.66M	Sell	252,000 -8,000	-3%	-$156K	﹤0.01%	1984
2016 Q3	$5.91M	Buy	+260,000	New	+$6.1M	﹤0.01%	1873
2016 Q2	–	Sell	-36,500	Closed	-$745K	–	8101
2016 Q1	$745K	Buy	+36,500	New	+$1.16M	﹤0.01%	3483

UBS Group's PTLA Position: Q3 2020 in Review

UBS Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 13,084 shares — an estimated $236K sold.

UBS Group first reported a position in PTLA in Q4 2014 and held it in 23 quarters. The position peaked at $6.54M in Q4 2018. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

UBS Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
UBS Group sold 13,084 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $236K.
UBS Group first reported a position in Portola Pharmaceuticals, Inc. in Q4 2014 and held it in 23 quarters.
UBS Group's Portola Pharmaceuticals, Inc. position peaked at $6.54M in Q4 2018.
0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on UBS Group's 13F filing for Q3 2020, filed 12 Nov 2020.